Product information per respective product insert. Viscosity measurements vary per methods reported in respective product package insert.

• Unique dual-property viscoadaptive-behaves like a cohesive and a dispersive agent
• Designed to maximize control throughout surgery
• Helps provide better-controlled capsulorrhexis⁴, phacoemulsification⁴, and lens placement^6,8
• Outstanding endothelial protection
• Latex free

• Allows surgeons to control its behavior by adjusting aspiration flow rates
• Possesses the highest zero shear viscosity of any viscoelastic (7,000,000 mPas)
• Acts like a cohesive agent at low flow rates to maintain the anterior chamber
• Acts like a dispersive agent at high flow rates to protect endothelial cells during phaco

• Remains in the anterior chamber during phacoemulsification for exceptional control of the intraocular environment^5,6
• Separates tissues for enhanced maneuverability^5,6

• Offsets positive pressure^6,8
• Maintains inflation of the capsular bag throughout lens implantation^6,8
• Minimizes the risk of developing a shallow anterior chamber

• Provides greater endothelial cell protection than the dispersive agent⁵ VISCOAT® and Ocucoat® OVD⁵
• Separates tissues during phacoemulsification for added protection^5,6
• Cushions delicate iris tissue and helps reduce the risk of iris prolapse^4,5
• Helps control unfolding of the intraocular lens^4,5

References

1. Hütz WW, Eckhardt HB, Kohnen T. Comparison of viscoelastic substances used in phacoemulsification. J Cataract Refract Surg. 1996;22(11):955-959.
2. Data on file, Advanced Medical Optics, Inc.
3. Buratto L, Giardini P, Bellucci R. Viscoelastics In Ophthalmic Surgery. Thorofare, NJ: Slack Inc; 2005:5.
4. Holmen J JB, Lundgren B. Scheimpflug photography study of ophthalmic viscosurgical devices during simulated cataract surgery. J Cataract Refract Surg. 2003;29(3):568-574.
5. Claesson M. A comparative study between Healon5 and Viscoat. Paper presented at: The XVI Congress of the European Society of Cataract and Refractive Surgeons (ESCRS);September 1998; Nice, France.
6. Tetz M. Protective study on endothelial cell protection with the use of different viscoelastic agents including Healon5. Paper presented at: The XVI Congress of the European Society of Cataract and Refractive Surgeons (ESCRS); September 1998; Nice, France.
7. Arshinoff S. Viscous-retentive ophthalmic viscoelastics. Paper presented at: The XVI Congress of the European Society of Cataract and Refractive Surgeons (ESCRS);September 1998; Nice, France.
8. Holzer MP, Tetz MR, Auffarth GU,Welt R, Volcker HE. Effect of Healon5 and 4 other viscoelastic substances on intraocular pressure and endothelium after cataract surgery. J Cataract Refract Surg.2001;27(2):213-218.

Intended use statement

Healon®, Healon GV®, and Healon5® OVDs are used in ophthalmic surgical procedures to maintain deep anterior chamber, which facilitates manipulation inside the eye with reduced trauma to the corneal endothelium and other ocular tissues. Vitrax® OVD is indicated for use as a surgical aid in the following ophthalmic surgical procedures: cataract surgery with an intraocular lens, cataract surgery without an intraocular lens, secondary intraocular lens implantation, corneal transplant surgery, and glaucoma filtration surgery. Warnings/Precautions/Contraindications: There are no known contraindications to the use of Healon®, Healon GV®, Healon5®, and Vitrax® ophthalmic viscoelastic devices when used as recommended. Please refer to package inserts for full prescribing information. Rx only.